Conmed (CNMD) Common Equity (2010 - 2026)

Conmed has reported Common Equity for 17 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 4.1% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 4.1% YoY), and the FY2025 full-year result was $1.0 billion, up 7.31% from the prior year.
• Common Equity for Q1 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• The five-year high for Common Equity was $1.0 billion in Q4 2025, with the low at $673.0 million in Q2 2022.
• Historically, Common Equity has averaged $868.2 million across 5 years, with a median of $854.7 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity decreased 9.61% — and 2024, when it advanced 17.17%.
• Conmed's Common Equity stood at $745.5 million in 2022, then grew by 11.89% to $834.2 million in 2023, then gained by 15.4% to $962.7 million in 2024, then advanced by 7.31% to $1.0 billion in 2025, then retreated by 1.49% to $1.0 billion in 2026.
• The last three Common Equity figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.